Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ziconotide is a synthetic peptide analgesic derived from the venom of the marine cone snail Conus magus. It is used for the management of severe chronic pain in patients who are refractory to other treatments, such as intrathecal morphine or systemic analgesics. Ziconotide acts as a potent and selective blocker of N-type voltage-gated calcium channels (specifically those containing the α1B subunit, also known as CaV2.2) located primarily in the dorsal horn of the spinal cord. By inhibiting these channels, ziconotide prevents neurotransmitter release from primary nociceptive afferents and blocks pain signal transmission to the brain. The drug is administered exclusively via intrathecal infusion due to its peptide nature and narrow therapeutic window. Ziconotide does not cause tolerance with chronic use but can be associated with significant neuropsychiatric side effects and must be dosed carefully under medical supervision[3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ziconotide.